The Claim
Bimagrumab treatment in adults with sarcopenia increases thigh muscle volume by approximately 5.29% and fat-free body mass by 1.90 kg on average, while reducing fat body mass by 4.55 kg, based on pooled data from seven randomized controlled trials with follow-up periods of 12 to 48 weeks.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with sarcopenia, bimagrumab increases thigh muscle volume by about 5.29%, adds 1.90 kg of fat-free mass, and reduces fat mass by 4.55 kg on average, based on combined results from seven randomized trials lasting 12 to 48 weeks.
See the scientific wording
Bimagrumab treatment in adults with sarcopenia increases thigh muscle volume by approximately 5.29% and fat-free body mass by 1.90 kg on average, while reducing fat body mass by 4.55 kg, based on pooled data from seven randomized controlled trials with follow-up periods of 12 to 48 weeks, indicating a consistent pharmacological effect on body composition despite variability in dosing and population characteristics.
A drug blocks signals that normally stop muscle growth and promote fat storage. This allows muscles to grow larger and the body to burn fat, increasing lean mass and reducing fat mass.
What the research says
1 studyStudy: Effect of Bimagrumab on body composition: a systematic review and meta-analysis
Bimagrumab helped people with muscle loss gain more muscle and lose fat, exactly as the claim says — and it didn’t make them stronger or faster overall, which the study also found.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.